(Q73916896)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

International Childhood Acute Lymphoblastic Leukemia Workshop: Sausalito, CA, 30 November-1 December 2000 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

main subject

lymphoblastic leukemia

1 reference

C H Pui

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

S Sallan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M V Relling

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

G Masera

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

W E Evans

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 May 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

707-715

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11368430%20AND%20SRC:MED&resulttype=core&format=json

Acute lymphoblastic leukemia

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Long-term results of large prospective trials in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Meeting report: International Childhood ALL Workshop: Memphis, TN, 3-4 December 1997.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Hematologic malignancies with t(4;11)(q21;q23)--a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

New definition of remission in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Clinical significance of glucocorticoid pharmacodynamics assessed by antilymphocyte action in kidney transplantation. Marked difference between prednisolone and methylprednisolone.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Ubiquitin-dependent protein degradation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Proteasome inhibition: a new strategy in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Agents that Down-Regulate or Inhibit Protein Kinase C Circumvent Resistance to 1-β-D-Arabinofuranosylcytosine-Induced Apoptosis in Human Leukemia Cells that Overexpress Bcl-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

The Bcl-2 protein family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

The CAMPATH-1 antigen (CDw52)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Campath-1H monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402111

7 January 2021